International Medical Research Frontier

Objective To analyze the effect of levofloxacin on multidrug-resistant pulmonary tuberculosis. Methods From February 2023 to January 2025, 72 patients with multi drug resistant pulmonary tuberculosis were randomly selected from Xintai Hospital of Traditional Chinese Medicine in Shandong Province, and 72 patients were randomly divided into two groups by computer random double-blind method. The experimental group received routine anti tuberculosis treatment with levofloxacin, while the control group received routine anti tuberculosis treatment. Compare indicators such as the closure time of pulmonary cavities. Results Regarding the total effective rate, the experimental group had a rate of 94.44%, while the control group had a rate of 72.22%, P＜0.05。 The closure time of pulmonary cavities, the time for tuberculosis bacilli to turn negative in sputum examination, and the time for lung lesion absorption were significantly different between the experimental group (71.51 ± 7.28) days, (38.04 ± 4.16) days, and (65.94 ± 6.03) days, and the control group (93.27 ± 9.13) days, (56.84 ± 7.12) days, and (91.59 ± 19.12) days (P<0.05). Adverse reactions: 8.33%, control group 13.89%, P＞0.05。 SF-36 score: After treatment, the experimental group scored (88.94 ± 3.02) points, while the control group scored (82.17 ± 4.54) points, with a significant difference (P<0.05). Conclusion Levofloxacin can significantly improve the efficacy, recovery and prognosis of multidrug resistant pulmonary tuberculosis patients during routine antituberculosis treatment, with less adverse reactions.

Multidrug resistant pulmonary tuberculosis; Pharmaceutical analysis; Levofloxacin; Sputum conversion rate